What is Bexorg?
Bexorg is a privately held company at the forefront of CNS drug discovery and development. It leverages the world's first integrated AI and whole-human brain platform, known as BrainEx. Founded by Dr. Zvonimir Vrselja and Dr. Nenad Sestan at Yale University, Bexorg combines its proprietary BrainEx platform with advanced AI models to create a highly predictive system for neuroscience research. The company operates with a strong commitment to rigorous legal frameworks and bioethics standards, guided by an independent board of experts, ensuring responsible innovation in a sensitive field.
How much funding has Bexorg raised?
Bexorg has raised a total of $23M across 1 funding round:
Series A
$23M
Series A (2025): $23M with participation from Little Engine Ventures, Connecticut Innovations, Amplify Partners, and Starbloom Capital
Key Investors in Bexorg
Little Engine Ventures
Little Engine Ventures specializes in niche service companies, focusing on fleet owners, skydiving enthusiasts, and advanced manufacturers. Their investment in Bexorg suggests an interest in companies with unique operational models and potential for regional expansion.
Connecticut Innovations
Connecticut Innovations is the state's strategic venture capital arm, providing financing and guidance to innovative companies, particularly in sectors like AI and biosciences. Their participation indicates a focus on supporting cutting-edge biotech ventures within their investment mandate.
Starbloom Capital
Starbloom Capital invests in breakthrough innovations in neuroAI, longevity, and deep tech, partnering with founders pushing scientific frontiers. Their involvement with Bexorg highlights a strong alignment with the company's neuroAI focus and its potential to advance human potential in neuroscience.
What's next for Bexorg?
With this recent major strategic investment, Bexorg is poised to accelerate its mission of transforming CNS drug discovery. The substantial capital infusion will likely fuel further development of its integrated AI and whole-human brain platform, enhancing its capabilities in creating clinically predictive systems. This funding will also support expansion of research initiatives, potential strategic partnerships, and the scaling of operations to meet the growing demands in neuroscience and drug development. Bexorg's focus on rigorous scientific standards and ethical practices positions it for sustained leadership and impact in addressing complex neurological conditions.
See full Bexorg company page
